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T he Centers for Medicare and Medicaid Services(CMS) in the United States have recently approvedambulatory blood pressure measurement (ABPM)
for reimbursement, but only for “patients with suspected
WCH (white coat hypertension)” in whom the CMS be-
lieves the information deriving from the technique “is
necessary in order to determine the appropriate manage-
ment of the patient.”1 This decision, which is likely to
change the clinical management of hypertension in the
United States, makes white coat hypertension a condition
of major importance. The decision by the CMS begs the
question as to how the practicing physician can select
patients with white coat hypertension. It might indeed be
argued that all patients with an elevated clinic blood
pressure (BP) are candidates for ABPM. However, the
CMS decision carries a few other stipulations. First, white
coat hypertension should be defined as “office BP
140/90 mm Hg on at least three separate clinic/office
visits with two separate measurements made at each visit.”
Second, in addition “there should be at least two BP
measurements taken outside the office which are 140/90
mm Hg.” Third, “there should be no evidence of end-
organ damage.” Fourth and last, patients selected for
ABPM on the foregoing criteria who have” an ambulatory
BP 135/85 (presumably average daytime pressure, al-
though this is not stated) with no evidence of end-organ
damage” are likely to be at normal risk, whereas those
patients whose pressures are above this level “may be at
increased cardiovascular risk, and a physician may wish to
consider antihypertensive therapies.”1
In anticipation of a considerable increase in the use of
ABPM in clinical practice in the United States, it is timely
to examine the CMS recommendations in the light of
recent evidence from a number of studies on WCH.
Definition of White
Coat Hypertension
The CMS decision is dependent on the definition of
WCH,1 which is a term used to denote individuals with
abnormally elevated BP in the medical environment and
normal BP during usual daily life.2,3 The most popular
definition of white coat hypertension is that BP measured
by conventional techniques in the office, clinic, or surgery
exceeds 140 mm Hg systolic or 90 mm Hg diastolic, but
when ABPM is performed the average BP is less than 135
mm Hg systolic and 85 mm Hg diastolic during the
daytime period.4 Currently, an average daytime ABPM of
less than 135 mm Hg systolic and 85 mm Hg diastolic is
generally considered normal and levels less than 130/80
mm Hg are considered optimal.4–8 The CMS stipulations
on definition of WCH are in line, therefore, with the
evidence from the literature.
Although, the CMS decision does not mention self
measurement of BP, this is implied in that a potential
candidate for ABPM must not only have an office BP
greater than 140/90 mm Hg measured twice on three
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separate clinic visits, but two measurements outside the
office should be less than 140/90 mm Hg; these latter
measurements would only be obtainable using a self mea-
surement technique. Self-measured home BP has been
used to identify subjects with white coat hypertension,3
though its role in this regard remains to be validated in
further clinical studies.9 Subject to this caveat a Report of
the First International Consensus Conference on self-mea-
sured home BP recommended that the upper limit of
normal home BP should be 135/85 mm Hg based on the
average of two measurements in the morning and in the
evening for at least 3 working days.10 So again, although
there may be a little difference in the detail, the CMS
stipulations in this regard are in line with current evidence.
Although on the issue of definition, it is important to be
clear on the terms being used, and WCH should be dis-
tinguished from white coat effect, which is the difference
between clinic BP and ABPM, regardless of the normality
or otherwise of either BP. Therefore, white coat effect is
present in virtually all hypertensive subjects,11 whereas
WCH is considered a normal or near-normal phenomenon.
White coat effect has been the subject of several stud-
ies.11–16
Clinical Significance of
White Coat Hypertension
Another important stipulation in the CMS decision is that
potential patients for ABPM should have no evidence of
end organ damage.1 However, the means whereby a prac-
ticing physician is to determine the end organ status of a
patient is not stipulated. Perhaps this recommendation
should be taken as a broad means of excluding those
patients with severe hypertension, who will have had an
electrocardiograph and echocardiograph as part of special-
ized work-up rather than a call for intensive and expensive
investigations in patients with WCH in whom such inves-
tigations are likely to be negative.
The clinical significance of WCH has become clearer
from a growing mass of data, including some event-based
cohort studies,17–21 which suggest that subjects with ele-
vated office/clinic BP, who have normal average daytime
pressures on ABPM have a risk of major cardiovascular
events comparable to that of clinically normotensive sub-
jects and less than that of subjects with elevated daytime
pressures.
In a study by Verdecchia and co-workers,17 event risk
was comparable between clinically normotensive controls
and subjects with white coat hypertension (defined as an
average daytime ABPM of less than 130 mm Hg systolic
and 80 mm Hg diastolic), whereas risk increased with
higher ABPM values. Likewise, in a study by Kario and
co-workers,19 the risk of stroke was comparable between
clinically normotensive individuals and subjects with
white coat hypertension (defined as an average daytime
ABPM of less than 135 mm Hg systolic and 85 mm Hg
diastolic). Fagard and co-workers,18 who analyzed the
Syst-Eur study dataset in older subjects with isolated sys-
tolic hypertension, found treatment more effective than
placebo in preventing events in subjects with moderate
sustained hypertension, defined by an average daytime
ABPM 160 mm Hg, but not in those with white coat
hypertension. On the other hand, some studies have sug-
gested that patients with WCH may be at increased
risk.20,21 The results of studies with large cohorts, which
should include the elderly with isolated systolic hyperten-
sion, are needed to confirm these findings.5,6 Nonetheless,
the CMS decision regarding risk is again in keeping with
the evidence.
The CMS decision makes the important recommenda-
tion that treatment may not be required in patients shown
to have WCH with ABPM. Overall, evidence to date,
however, does not allow us to make firm recommendations
regarding drug treatment in subjects with white coat hy-
pertension. Antihypertensive drug treatment would seem
to be unnecessary in most subjects with uncomplicated
white coat hypertension.22 However, intervention studies
are needed to determine whether subjects with white coat
hypertension might benefit from treatment to prevent the
future development of organ damage and risk of cardio-
vascular events. In a study by Staessen and co-workers,23
adjustment of antihypertensive treatment based on either
ABPM or clinic BP resulted in less intensive drug treat-
ment in the ABPM group despite comparable BP control
in both groups, and importantly, patients in the ABPM
group, who received less drug treatment were not disad-
vantaged as judged by left ventricular mass on echocardi-
ography. At least on the basis of this study, the CMS
suggestion that patients with WCH may not need antihy-
pertensive medication, is reasonable.
A further point deserves mention. The ABPM levels in
subjects defined as having white coat hypertension could
represent, by chance, a sample taken at the low extreme of
their random distribution. Consequently, day-to-day repro-
ducibility of white coat hypertension might be impaired by
a regression-to-the-mean phenomenon. In one study, di-
agnosis of white coat hypertension was not reproducible in
as many as 58% of the subjects.24 More data are needed,
therefore, to elucidate the issue of reproducibility of white
coat hypertension.
Identification of Subjects
With White Coat Hypertension
Several hypertension guidelines25–27 stipulate that sus-
pected WCH is an indication for ABPM, and this presum-
ably influenced the CMS decision. However, the guide-
lines do not elaborate as to how the practicing physician
may “suspect” WCH, and in fairness it has to be admitted
that data allowing an estimate of the probability of WCH
according to the clinical characteristics of subjects are
very scarce.
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In a study carried out in 292 subjects with office dia-
stolic BP between 90 and 104 mm Hg, female gender,
young age, and hypertension of short duration were inde-
pendent predictors of WCH.2 The analysis of a large
international database composed of 2492 subjects with
office BP more than 140 mm Hg systolic or 90 mm Hg
diastolic showed that the probability of having WCH
(defined as an average 24-h ABPM below the 95th centile
of a normotensive control group) was greater in women,
directly associated with age and inversely associated with
office BP and the number of BP measurements in the
office.28 Thus, the role of age as a predictor of WCH is
controversial. In another analysis of 1333 subjects in the
Progetto Ipertensione Umbria Monitoraggio Ambulato-
riale (PIUMA) database,11 prevalence of white coat hy-
pertension was 33.3% in Joint National Committee Stage
I (systolic 140 to 159 mm Hg or diastolic BP 90 to 99 mm
Hg), 11.8% in stage II (systolic 160 to 179 mm Hg or
diastolic BP 100 to 109 mm Hg) and 3% in stage III
(systolic 180 mm Hg or diastolic BP 110 mm Hg).
These data indicate the higher probability of white coat
hypertension in stage I hypertensive subjects. Recent stud-
ies in children have confirmed the findings in adults that
WCH is more frequent in patients with milder (stage I)
hypertension.29
Recently, a joint analysis of the Hypertension and Am-
bulatory Recording Venetia Study and PIUMA databases
examined 1564 subjects with uncomplicated stage I hy-
pertension30 from which subjects with diabetes mellitus,
hypertension greater than stage I, renal failure, and previ-
ous cardiovascular events were excluded. Multivariate lo-
gistic regression analysis showed that lower values of
office diastolic BP (P .0002), female gender (P .002),
and nonsmoking status (P  .038) were the sole indepen-
dent predictors of WCH. In the subjects with adequate
echocardiographic tracings, a smaller value of left ventric-
ular mass was a further independent predictor (P  .002)
of WCH.
In a recent study, a lower body mass index and a more
favorable lipid profile characterized subjects with future
(after 20 years) development of white coat hypertension as
opposed to those with future sustained hypertension.31
Left ventricular mass and prevalence of microalbuminuria
did not differ between subjects with white coat hyperten-
sion, a clinically normotensive control group, whereas
circulating glucose and insulin levels were higher in the
white coat hypertension group than in the normotensive
group.31
Overall, these data indicate that in untreated subjects
with essential hypertension, the probability of WCH in-
creases in subjects with 1) office systolic BP 140 to 159
mm Hg or diastolic BP 90 to 99 mm Hg, 2) female gender,
3) nonsmokers, 4) hypertension of recent onset, 5) limited
number of BP measurements in the office, and 6) small left
ventricular mass.
Conclusions
Taking account, therefore, of the CMS recommendations,1
can this analysis of the available evidence give additional
help to the practicing physician in deciding which subject
with elevated office BP and suspected WCH should or
should not have ABPM? In truth, it must be admitted that
it is difficult to escape the conclusion that all patients in
whom a diagnosis of hypertension is being contemplated
based on office/clinic BP, should have ABPM to exclude
WCH, but there are at least some features that may make
it more likely that an elevated office BP is due to WCH.
First, subjects (they are not necessarily patients) with
office systolic BP between 140 and 159 mm Hg or dia-
stolic BP between 90 and 99 mm Hg should have ABPM
to exclude WCH, because about 33% of these subjects
may have the condition.12 In contrast, ABPM will only
identify a small number of subjects with WCH when office
BP is higher. Thus, if resources are limited ABPM should
not be used in these subjects solely to identify WCH.
Second, there is some evidence to suggest that the likeli-
hood of identifying WCH is increased in subjects with at
least one of the following conditions: female sex, non-
smoking status, recent diagnosis of hypertension, limited
number of BP measurements in the doctor’s office, and
small left ventricular mass at echocardiogram. Third,
many patients may already be aware that their BP is higher
in the physician’s office than outside it, and the likelihood
of WCH11,12 makes them candidates for ABPM for sus-
pected WCH.
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